Analystreport

Aclaris Therapeutics Inc (NASDAQ: ACRS) was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock.

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com